Breast Carcinoma in Situ

• CLINICAL_TRIALS trial_result · 2026-08-28
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active-not-recruiting.

• CLINICAL_TRIALS trial_result · 2026-07-31
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 trial exploring pembrolizumab as adjuvant therapy for triple-negative breast cancer is actively not recruiting.

• CLINICAL_TRIALS trial_result · 2026-07-02
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 clinical trial update for pembrolizumab as adjuvant therapy in triple-negative breast cancer, status ACTIVE_NOT_RECRUITING.

• CLINICAL_TRIALS trial_result · 2026-07-01
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer is ongoing with active status.

• CLINICAL_TRIALS trial_result · 2026-06-25
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; ongoing ACTIVE_NOT_RECRUITING trial …

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2026-06-03
  Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]

  Phase 3 trial investigating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; currently active but not recruiti…